NEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2023

ADVERTISEMENT RETURN TO BOOKPREVChapterNEXTNEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2023David W. LinDavid W. LinGilead Sciences, Foster City, California, U.S.AMore by David W. Lin, Megan ArmstrongMegan ArmstrongGilead Sciences, Foster City, California, U.S.AMore by Megan Armstrong, Jennifer JiangJennifer JiangGilead Sciences, Foster City, California, U.S.AMore by Jennifer Jiang, Juan del PozoJuan del PozoMerck & Co., Inc., Boston, Massachusetts, U.S.AMore by Juan del Pozo, and Christiana N. TeijaroChristiana N. TeijaroBristol Myers Squibb, Lawrenceville, New Jersey, U.S.AMore by Christiana N. TeijaroDOI: 10.1021/mc-2024-vol59.ch18Publication Date (Web):November 18, 2024Publication HistoryPublished online18 November 2024Request reuse permissions Copyright © 2024 MEDI, Inc. Published by American Chemical Society.2024 Medicinal Chemistry ReviewsChapter 18pp 399-414Medicinal Chemistry ReviewsVol. 59ISBN13: 9781734427493eISBN: 9781734427486Chapter Views-Citations-LEARN ABOUT THESE METRICSChapter Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts. Share ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookXWeChatLinkedInRedditEmail Other access options Get e-Alerts